Takeda Pharmaceutical Company Limited (TAK)
NYSE: TAK · Real-Time Price · USD
18.86
+0.27 (1.45%)
At close: Sep 25, 2026, 4:00 PM EDT
18.86
0.00 (0.00%)
After-hours: Sep 25, 2026, 4:41 PM EDT
Takeda Pharmaceutical Revenue
Takeda Pharmaceutical had revenue of 1.22T JPY in the quarter ending June 30, 2026, with 10.23% growth. This brings the company's revenue in the last twelve months to 4.62T, up 4.57% year-over-year. In the fiscal year ending March 31, 2026, Takeda Pharmaceutical had annual revenue of 4.51T, down -1.66%.
Revenue (ttm)
4.62T JPY
Revenue Growth
+4.57%
P/S Ratio
2.13
Revenue / Employee
98,213,783 JPY
Employees
47,029
Market Cap
60.57B USD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 4.51T | -75.83B | -1.66% |
| Mar 31, 2025 | 4.58T | 317.79B | 7.45% |
| Mar 31, 2024 | 4.26T | 236.28B | 5.87% |
| Mar 31, 2023 | 4.03T | 458.47B | 12.85% |
| Mar 31, 2022 | 3.57T | 371.19B | 11.61% |
| Mar 31, 2021 | 3.20T | -93.38B | -2.84% |
| Mar 31, 2020 | 3.29T | 1.19T | 56.93% |
| Mar 31, 2019 | 2.10T | 326.69B | 18.45% |
| Mar 31, 2018 | 1.77T | 38.48B | 2.22% |
| Mar 31, 2017 | 1.73T | -75.33B | -4.17% |
| Mar 31, 2016 | 1.81T | 29.55B | 1.66% |
| Mar 31, 2015 | 1.78T | 86.14B | 5.09% |
| Mar 31, 2014 | 1.69T | 134.42B | 8.63% |
| Mar 31, 2013 | 1.56T | 48.34B | 3.20% |
| Mar 31, 2012 | 1.51T | 89.55B | 6.31% |
| Mar 31, 2011 | 1.42T | -46.58B | -3.18% |
| Mar 31, 2010 | 1.47T | -72.37B | -4.70% |
| Mar 31, 2009 | 1.54T | 163.53B | 11.90% |
| Mar 31, 2008 | 1.37T | 69.64B | 5.34% |
| Mar 31, 2007 | 1.31T | 92.96B | 7.67% |
| Mar 31, 2006 | 1.21T | 89.25B | 7.95% |
| Mar 31, 2005 | 1.12T | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Teva Pharmaceutical Industries | 17.32B |
| Haleon | 14.80B |
| Viatris | 14.74B |
| Zoetis | 9.53B |
| Elanco Animal Health | 5.02B |
| Dr. Reddy's Laboratories | 3.50B |
| Neurocrine Biosciences | 3.37B |
| United Therapeutics | 3.15B |
TAK News
- 2 days ago - Roche proposes former Takeda CEO for board seat - Reuters
- 3 days ago - Takeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-Breaking Phase 3 Arcotatug Tavatecan (TAK-921) Data, at ESMO 2026 - Business Wire
- 4 days ago - Takeda Unveils $22.2 Mln CSR Collaborations Focused On Climate-Resilient Health; Stock Up - Nasdaq
- 7 days ago - Dengue vaccine to hit market by first half of 2027 - The Times of India
- 7 days ago - Takeda Employees Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems - Business Wire
- 7 days ago - India's Dr Reddy's inks distribution agreement with Takeda for dengue vaccine in India - Reuters
- 9 days ago - Takeda Pharmaceutical (TAK) Insider Sale: Chief Transformation Officer Lauren Duprey Sells ... - GuruFocus
- 11 days ago - Takeda Pharmaceutical Company Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts